title: Th2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo.
abstract: The immune suppression that characterizes human helminth infections can hinder the development of protective immunity or help to reduce pathogenic inflammation. Signaling through the T cell costimulator glucocorticoid-induced TNFR-related protein (GITR) counteracts immune downregulation by augmenting effector T cell responses and abrogating suppression by Foxp3(+) regulatory T cells. Thus, superphysiological Ab-mediated GITR costimulation represents a novel therapy for promoting protective immunity toward parasitic helminths, whereas blocking physiological GITR-GITR ligand (GITRL) interactions may provide a mechanism for dampening pathogenic Th2 inflammation. We investigated the superphysiological and physiological roles of the GITR-GITRL pathway in the development of protective and pathogenic Th2 responses in murine infection models of filariasis (Litomosoides sigmodontis) and schistosomiasis (Schistosoma mansoni). Providing superphysiological GITR costimulation using an agonistic anti-GITR mAb over the first 12 d of L. sigmodontis infection initially increased the quantity of Th2 cells, as well as their ability to produce Th2 cytokines. However, as infection progressed, the Th2 responses reverted to normal infection levels, and parasite killing remained unaffected. Despite the Th2-promoting role of superphysiological GITR costimulation, Ab-mediated blockade of the GITR-GITRL pathway did not affect Th2 cell priming or maintenance during L. sigmodontis infection. Blockade of GITR-GITRL interactions during the acute egg phase of S. mansoni infection resulted in reduced Th2 responses, but this effect was confined to the spleen and did not lead to changes in liver pathology. Thus, although superphysiological GITR costimulation can therapeutically enhance Th2 responses, physiological GITR-GITRL interactions are not required for the development of Th2-mediated resistance or pathology in murine models of filariasis and schistosomiasis.
authors.affiliation: Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom.
authors.forename: Nienke
authors.initials: N
authors.lastname: van der Werf
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Redpath
authors.forename: Alexander T
authors.initials: AT
authors.lastname: Phythian-Adams
authors.forename: Miyuki
authors.initials: M
authors.lastname: Azuma
authors.forename: Judith E
authors.initials: JE
authors.lastname: Allen
authors.forename: Rick M
authors.initials: RM
authors.lastname: Maizels
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Macdonald
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Taylor
mesh_terms: D000818:Animals; D005260:Female; D005368:Filariasis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005370:Filarioidea / Q000276:immunology*; D053450:Glucocorticoid-Induced TNFR-Related Protein / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D008024:Ligands; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D012550:Schistosoma mansoni / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000276:immunology / Q000473:pathology / Q000628:therapy; D018418:Th2 Cells / Q000276:immunology* / Q000469:parasitology* / Q000473:pathology; D048069:Tumor Necrosis Factors / Q000235:genetics / Q000378:metabolism*
chemical_list: D053450:Glucocorticoid-Induced TNFR-Related Protein; D008024:Ligands; C491405:TNFRSF18 protein, human; C478967:TNFSF18 protein, human; D048069:Tumor Necrosis Factors